SPR Therapeutics is committed to improving the lives of millions of pain sufferers with its peripheral nerve stimulation (PNS) platform technology poised to be the standard of care and ultimately, the treatment of choice for pain management.
Led by a world-class team of scientists, physicians, and business professionals with a track record of commercializing innovative neurostimulation products, SPR’s PNS therapy for acute and chronic pain management provides a non-narcotic, reversible, safe, effective and more affordable alternative to addictive opioid medications and invasive surgeries.
Large underserved markets
We are actively investigating, developing and commercializing therapies aimed at the following large market opportunities:
Musculoskeletal pain
Pain in the joints and muscles such as shoulder pain and low back pain
Neuropathic pain
Pain following nerve injury or nerve surgery such as phantom limb pain
Post-surgical pain
Pain following surgery such as knee replacement, thoracotomy* and rotator cuff repair*
*Areas for future research
Our Team
SPR Therapeutics is led by an experienced management team with a long history of success in researching, developing and commercializing neurostimulation products. Our clinical and scientific advisors are also renowned worldwide as leaders in interventional pain management, rehabilitation medicine, orthopedics and biomedical engineering.
Executive Management
Maria E. Bennett
President, CEO and Founder
Ben Austin, CPA
Chief Financial Officer
Joseph Boggs Ph.D
Chief Scientific Officer
Todd Davis
Vice President, Market Access
Michelle McDonald
Vice President, Marketing
Kathryn Stager
Vice President, Regulatory, Quality, & New Product Development; Compliance Officer
David Youngberg
Senior Vice President, Sales
Scientific and Clinical Advisors
Peter Staats MD, MBA, DABA, ABIPP, FIPP
Chief Medical Advisor
Warren Grill Ph.D
Chief Scientific Advisor
Marc Huntoon MD
Director of Medical Affairs
Board of Directors
Geoffrey B. Thrope
Chairman
Maria E. Bennett
President, CEO and Founder
Robert M. Blankenship
Managing Director
Michael P. Chuisano
Managing Director
Nicholas J. Valeriani
Managing Director